Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC

Xie, Fan; Li, P.; Gong, Jianhua; Tan, Hongxia; Ma, Jin

doi:10.1007/s12094-017-1754-7

Cited by 20 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were obtained by Li et al (2017). Mutant KRAS was detected in urine with 95% concordance with primary tissue biopsy (Wang et al, 2017) from an NSCLC patient cohort and longitudinal monitoring of urine specimens revealed association with disease progression and outcome (Wang et al, 2017;Xie et al, 2018) as well as the potential to assess therapeutic response (Tchekmedyian et al, 2017).…”

Section: Nonsmall Cell Lung Cancersupporting

confidence: 73%

Urine-Based Liquid Biopsy for Nonurological Cancers

Jain

Lin

Song

et al. 2019

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

The use of circulating cell-free DNA for detection of cancer genetics has been studied extensively. Liquid biopsy often refers to the use of blood as a minimally invasive source of body fluid for detecting circulating tumor DNA (ctDNA). However, urine collection, which is completely noninvasive, has been shown to also have great promise to serve as an alternate body fluid source for ctDNA. In this review article, we focus on the clinical utility of urine for genetic liquid biopsy of nonurological cancers. Conclusion: Although still in early stages as compared with blood-based liquid biopsy, recent studies have demonstrated the value of urine-based liquid biopsies for: nonurological cancer screening; early detection; monitoring for recurrence and metastasis; and therapeutic efficacy. Overall, the completely noninvasive and patient-friendly nature of the urine-based biopsy warrants further development and offers a promising alternative to blood-based biopsies.

show abstract

Section: Nonsmall Cell Lung Cancersupporting

confidence: 73%

Urine-Based Liquid Biopsy for Nonurological Cancers

Jain

Lin

Song

et al. 2019

Genetic Testing and Molecular Biomarkers

View full text Add to dashboard Cite

show abstract

“…In addition, tumor cells undergo dynamic genetic and epigenetic changes through time (due to therapeutic stress [6], for example), resulting in further tumoral heterogeneity and in discrepancies between primary and metastatic lesions [5]. Thus, the spatially and temporally limited tissue biopsies fail to represent the overall tumor profile, to capture alterations from different sites and, consequently, to monitor disease progression [7].…”

Section: Of 20mentioning

confidence: 99%

“…Given this, in the recent years, research in oncology has focused on liquid biopsies, which rely on the detection of cancer-derived components, including circulating tumor cells (CTCs) [5,[8][9][10][11][12][13][14][15][16], circulating tumor DNA (ctDNA) [3,4,6,7,12,, RNA [10,[61][62][63][64][65], extracellular vesicles (EVs) [10,66], and tumor educated platelets (TEPs) [67], in the biofluids of patients, providing genomic [68,69], epigenetic [70,71], transcriptomic, and proteomic [72] information about tumors and metastatic sites. The use of liquid biopsies as a clinical tool will improve cancer screening [2], diagnosis [15,17,19,53,58,61,62] and prognosis [4,13,25,26,29,48,73], ameliorate the classification of more heterogeneous entities, and perform a tighter patient monitorization [56,…”

Section: Of 20mentioning

confidence: 99%

“…Besides blood, other biofluids, such as urine [7,23,28,37,39,47,52], cerebrospinal fluid (CSF) [60], and gastric washes [54], have been shown to harbor ctDNA. Depending on the type of cancer, tumors might more closely contact with different fluids that, consequently, might contain higher ctDNA concentrations than blood [23].…”

Section: Liquid Biopsies For Diagnosis and Tumor Profilingmentioning

confidence: 99%

See 1 more Smart Citation

Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring

Martins

Ribeiro

Jorge

et al. 2021

Genes

131

View full text Add to dashboard Cite

The minimally—or non-invasive detection of circulating tumor-derived components in biofluids, such as blood, liquid biopsy is a revolutionary approach with significant potential for the management of cancer. Genomic and transcriptomic alterations can be accurately detected through liquid biopsies, which provide a more comprehensive characterization of the heterogeneous tumor profile than tissue biopsies alone. Liquid biopsies could assist diagnosis, prognosis, and treatment selection, and hold great potential to complement current surveilling strategies to monitor disease evolution and treatment response in real-time. In particular, these are able to detect minimal residual disease, to predict progression, and to identify mechanisms of resistance, allowing to re-orient treatment strategies in a timelier manner. In this review we gathered current knowledge regarding the role and potential of liquid biopsies for the diagnosis and follow-up of cancer patients. The presented findings emphasize the strengths of liquid biopsies, revealing their chance of improving the diagnosis and monitoring of several tumor types in the near future. However, despite growing evidence supporting their value as a management tool in oncology, some limitations still need to be overcome for their implementation in the routine clinical setting.

show abstract

“…This approach also enables the identification of EGFR alterations that were not detected in tumour samples and could be used to monitor both treatment response and the development of acquired resistance. Similarly, analysis of the presence of KRAS mutations in trtDNA has shown high levels of concordance of around 70-77% relative to tissue sampling, which correlates favourably with plasma ctDNA 36 , as well as providing prognostic information for patients with elevated KRAS-mutant trtDNA at baseline 35,37 .…”

Section: Trial Enrolmentmentioning

confidence: 98%

Circulating tumour DNA — looking beyond the blood

et al. 2022

View full text Add to dashboard Cite

Over the past decade, various liquid biopsy techniques have emerged as viable alternatives to the analysis of traditional tissue biopsy samples. Such surrogate ‘biopsies’ offer numerous advantages, including the relative ease of obtaining serial samples and overcoming the issues of interpreting one or more small tissue samples that might not reflect the entire tumour burden. To date, the majority of research in the area of liquid biopsies has focused on blood-based biomarkers, predominantly using plasma-derived circulating tumour DNA (ctDNA). However, ctDNA can also be obtained from various non-blood sources and these might offer unique advantages over plasma ctDNA. In this Review, we discuss advances in the analysis of ctDNA from non-blood sources, focusing on urine, cerebrospinal fluid, and pleural or peritoneal fluid, but also consider other sources of ctDNA. We discuss how these alternative sources can have a distinct yet complementary role to that of blood ctDNA analysis and consider various technical aspects of non-blood ctDNA assay development. We also reflect on the settings in which non-blood ctDNA can offer distinct advantages over plasma ctDNA and explore some of the challenges associated with translating these alternative assays from academia into clinical use.

show abstract

Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC

Abstract: Urinary DNA offered a non-invasive approach to probe NSCLC dynamics, and in our study we showed that it had predictive capabilities for KRAS-positive patients. Serial monitoring of urinary samples showed that it had a predictive role in identifying patients with worse outcome.

Cited by 20 publications

References 33 publications

Urine-Based Liquid Biopsy for Nonurological Cancers

Urine-Based Liquid Biopsy for Nonurological Cancers

Liquid Biopsies: Applications for Cancer Diagnosis and Monitoring

Circulating tumour DNA — looking beyond the blood

Contact Info

Product

Resources

About